AtriCure (NASDAQ:ATRC) Stock Falls 6.2% – What’s Next?

Shares of AtriCure, Inc. (NASDAQ:ATRC) fell 6.2% during trading on Thursday. The stock traded as low as $52.60 and last traded at $52.7120. Approximately 1,021,907 shares were traded during trading, an increase of 17% from the average session volume of 875,922 shares. The stock had previously closed at $56.20.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Needham & Company LLC boosted their target price on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Stifel Nicolaus set a $65.00 price objective on AtriCure in a research report on Thursday, September 17th. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Finally, Piper Sandler lifted their target price on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.30.

AtriCure Trading Down 5.6%

The company’s 50 day simple moving average is $48.63 and its 200-day simple moving average is $36.08. The firm has a market cap of $2.70 billion, a P/E ratio of 252.05 and a beta of 1.26. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the sale, the director directly owned 14,015 shares of the company’s stock, valued at $538,456.30. The trade was a 19.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen Prange sold 3,564 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 74,868 shares of company stock valued at $3,317,897. 4.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ATRC. BlackRock Inc. purchased a new stake in AtriCure in the second quarter worth about $125,198,000. Wellington Management Group LLP increased its position in AtriCure by 3.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock valued at $97,807,000 after purchasing an additional 113,048 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of AtriCure by 8.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock valued at $28,466,000 after purchasing an additional 75,862 shares in the last quarter. GW&K Investment Management LLC raised its holdings in shares of AtriCure by 10.6% in the 4th quarter. GW&K Investment Management LLC now owns 952,089 shares of the medical device company’s stock valued at $37,665,000 after purchasing an additional 91,054 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of AtriCure in the 2nd quarter worth approximately $24,465,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.